What is CDx Diagnostics?
CDx Diagnostics operates at the intersection of molecular biology and artificial intelligence, providing a specialized diagnostic platform designed to address critical gaps in the current standard of care for esophageal cancer. The company utilizes a sophisticated combination of computer imaging and three-dimensional cytopathology to identify precancerous changes with higher reliability than traditional methods. By focusing on cost-effective, widely reimbursed testing, CDx Diagnostics has successfully integrated its solutions into routine clinical workflows, enabling physicians to detect thousands of conditions that might otherwise remain undiagnosed until later, more difficult stages of treatment. The firm is currently backed by Galen Partners, a private equity firm known for its focus on healthcare growth-stage investments.
How much funding has CDx Diagnostics raised?
CDx Diagnostics has raised a total of $13.5M across 2 funding rounds:
Unspecified
$11M
Series A
$2.5M
Unspecified (2019): $11M, investors not publicly disclosed
Series A (2025): $2.5M, investors not publicly disclosed
Key Investors in CDx Diagnostics
Galen Partners
A growth-oriented private equity firm specializing in healthcare and medical technology investments.
Undisclosed Investor
An undisclosed investor participating in the funding round to support the company's diagnostic expansion.
Undisclosed Investor
An undisclosed investor participating in the funding round to support the company's diagnostic expansion.
What's next for CDx Diagnostics?
With the infusion of $2.5M, CDx Diagnostics is well-positioned to scale its operational footprint and further refine its diagnostic algorithms. The company's strategic roadmap likely involves expanding its clinical reach and enhancing the integration of its AI-driven cytopathology tools within broader healthcare systems. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward increasing market penetration and establishing its platform as the definitive standard for esophageal cancer screening. Continued investment in molecular biology research will remain a cornerstone of its long-term value proposition, ensuring that the company maintains its competitive edge in the rapidly evolving medical technology landscape.
See full CDx Diagnostics company page
